Objective: To investigate the expression changes of thioredoxin (Trx) system in tumor necrosis factor-α (TNF-α) -induced psoriasis-like cell model, and to reveal its potential role in inflammation and oxidative damage of cell model. Methods: Human keratinocyte HaCaT cells were induced with TNF-α to establish a psoriasis-like inflammatory cell model. Cells were divided into a control group and a TNF-α model group. The CCK-8 assay was used to detect cell proliferation rate, ELISA was applied to measure inflammatory cytokine expression and cellular reactive oxygen species (ROS) levels, and Western blot was performed to analyze the protein expression of thioredoxin-1 (Trx-1) and thioredoxin reductase (TrxR). Results: Compared with the control group, the expression of TrxR in the TNF-α model group was decreased (P＜0.05); the expression of Trx-1 showed a downward trend, but there was no statistical significance; cell proliferation was increased (P＜0.001); the expression levels of inflammatory mediators TNF-α, IL-17 and IL-22 were increased (P＜0.001); the level of ROS was increased (P＜0.001). Conclusion: TNF-α can induce the decrease of TrxR expression in human epidermal keratinocytes, and increase the proliferation, inflammation and oxidative stress of epidermal keratinocytes, suggesting that abnormal expression of Trx system may be involved in TNF-α-induced psoriasis-like oxidative-inflammatory injury process.
JIA Dongwu
,
LIN Yi
,
LIU Xiaofang
,
YANG Sen
,
LIU Jia
,
ZHANG Kun
. Study on the role of thioredoxin system inTNF-α-induced oxidative-inflammatory damage of psoriasis-like cells[J]. Journal of Baotou Medical College, 2026
, 42(3)
: 45
-49
.
DOI: 10.16833/j.cnki.jbmc.2026.03.009
[1] Vaengebjerg S, Skov L, Egeberg A, et al. Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis[J]. JAMA Dermatology, 2020, 156(4):421-429.
[2] Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study[J]. BMJ (Clinical research ed), 2020, 369:m1590.
[3] Sieminska I, Pieniawska M, Grzywa TM. The Immunology of Psoriasis-Current Concepts in Pathogenesis[J]. Clin Rev Allergy Immunol, 2024, 66(2):164-191.
[4] Tampa M, Mitran MI, Mitran CI, et al. Psoriasis: What Is New in Markers of Disease Severity[J]. Medicina (Kaunas), 2024, 60(2):337.
[5] Jelic MD, Mandic AD, Maricic SM, et al. Oxidative stress and its role in cancer[J]. J Cancer Res Ther, 2021, 17(1):22-28.
[6] Kadam DP, Suryakar AN, Ankush RD, et al. Role of oxidative stress in various stages of psoriasis[J]. Indian J Clin Biochem.2010, 25(4):388-392.
[7] Xinastle-Castillo LO, Landa A. Physiological and modulatory role of thioredoxins in the cellular function[J]. Open Med (Wars), 2022, 17(1):2021-2035.
[8] Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis[J]. Lancet, 2021, 397(10281):1301-1315
[9] Kiafar B, Binabaj MM, Jafarian AH, et al. The Relationship between Tissue Thioredoxin Reductase Activity and the Psoriasis Area and Severity Index[J]. Indian J Dermatol, 2020, 65(1):29-32.
[10] Leone GM, Mangano K, Petralia MC, et al. Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy[J]. J Clin Med, 2023, 12(4):1630.
[11] Jang DI, Lee AH, Shin HY, et al. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics[J]. Int J Mol Sci, 2021, 22(5):2719.
[12] Surh YJ, Chun KS, Cha HH, et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation[J]. Mutat Res, 2001, 480-481:243-268.
[13] Yoo MH, Carlson BA, Gladyshev VN, et al. Abrogated thioredoxin system causes increased sensitivity to TNF-α-induced apoptosis via enrichment of p-ERK 1/2 in the nucleus[J]. PloS One, 2013, 8(9):e71427.
[14] Yeo EJ, Shin MJ, Yeo HJ, et al. Tat-thioredoxin 1 reduces inflammation by inhibiting pro-inflammatory cytokines and modulating MAPK signaling[J]. Exp Ther Med, 2021, 22(6):1395.
[15] Torres T, Puig L, Vender R, et al. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study[J]. Am J Clin Dermatol, 2021, 22(4):567-579.
[16] Nerviani A, Boutet MA, Tan WSG, et al. IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors[J]. Ann Rheum Dis, 2021, 80(5):591-597.
